



October 26, 2016

Tetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016

WATERTOWN, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- [Tetraphase Pharmaceuticals, Inc.](http://www.tetraphase.com) (NASDAQ:TTPH) today announced eight data presentations at IDWeek 2016, taking place October 26-30 in New Orleans, LA. Presentations will include information about the company's phase 3 antibiotic candidate, eravacycline, with data demonstrating consistent and potent *in vitro* activity against drug-resistant bacteria, including carbapenem-resistant *Enterobacteriaceae* (CRE), *Acinetobacter baumannii*, vancomycin-resistant enterococci (VRE) and methicillin-resistant *Staphylococcus aureus* (MRSA), isolated from recent patients. Additionally, national prevalence data focused on infections caused by resistant strains of *Enterobacteriaceae* and *Acinetobacter baumannii* will be presented suggesting that rates of these types of infections may be higher than previously reported estimates.

The details for the data presentations at IDWeek 2016 are as follows:

Eravacycline presentations:

Poster# 1820: *In vitro* global surveillance of eravacycline and comparators against *Staphylococcus spp.* and *Enterococcus spp.* over a three-year period (2013-15)

Date and time: Saturday, October 29 from 12:30 - 2:00 p.m. CT

Session info: Antibacterial Susceptibility Surveillance

Poster# 1825: *In vitro* global surveillance of eravacycline and comparators against *Enterobacteriaceae*, *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia*, including multidrug-resistant isolates, over a three-year period (2013-15)

Date and time: Saturday, October 29 from 12:30 - 2:00 p.m. CT

Session info: Antibacterial Susceptibility Surveillance

Poster# 1844: Eravacycline is Active against Carbapenem-resistant *Enterobacteriaceae* and *Acinetobacter baumannii* Isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank Panels

Date and time: Saturday, October 29 from 12:30 - 2:00 p.m. CT

Session info: Antibacterial Susceptibility Surveillance

Poster# 1851: The Susceptibility of Eravacycline and Comparators to Global Isolates of *Acinetobacter baumannii*

Date and time: Saturday, October 29 from 12:30 - 2:00 p.m. CT

Session info: Antibacterial Susceptibility Surveillance

Other Presentations:

Poster# 369: National Prevalence of Extended Spectrum Beta-lactamase-producing *Enterobacteriaceae* (ESBL) in the Ambulatory and Acute Care Settings in the United States in 2015

Date and time: Thursday, October 27 from 12:30 - 2:00 p.m. CT

Session info: HAI: Multi Drug Resistant Gram Negatives

Poster# 352: National Prevalence of Carbapenem-Resistant *Enterobacteriaceae* (CRE) in the Ambulatory and Acute Care Settings in the United States in 2015

Date and time: Thursday, October 27 from 12:30 - 2:00 p.m. CT

Session info: HAI: Multi Drug Resistant Gram Negatives

Poster# 378: National Prevalence of Multidrug-Resistance (MDR) in *Enterobacteriaceae* (ENT) in the Ambulatory and Acute Care Settings in the United States in 2015

Date and time: Thursday, October 27 from 12:30 - 2:00 p.m. CT

Session info: HAI: Multi Drug Resistant Gram Negatives

Poster# 1488: National Prevalence of Multidrug-Resistant *Acinetobacter baumannii* (MDR AB) infections in the Ambulatory and Acute Care Settings, Including Carbapenem-Resistant *Acinetobacter* Infections, In the United States in 2015

Date and time: Friday, October 28 from 12:30 - 2:00 p.m. CT

Session info: HAI: Surveillance and Public Reporting

IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). Full abstracts can be found on the ID Week website at <http://www.idweek.org/>.

About Eravacycline

Eravacycline is a novel, fully-synthetic tetracycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens that have been highlighted as urgent public health threats by both the World Health Organization and the U.S. Centers for Disease Control and Prevention (CDC). Eravacycline is Tetraphase's lead product candidate in phase 3 clinical development for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes its late-stage antibiotic, eravacycline, as well as two additional antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.

Investor Contacts:

Tetraphase Pharmaceuticals

Teri Dahlman

617-600-7040

tdahlman@tphase.com

Argot Partners

Maeve Conneighton

212-600-1902

maeve@argotpartners.com

Media Contact:

Sam Brown Inc.

Mike Beyer

312-961-2502

Mikebeyer@sambrown.com

 [Primary Logo](#)

Source: Tetraphase Pharmaceuticals

News Provided by Acquire Media